Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PLYX
STRONG SELLPolaryx Therapeutics, Inc. · Healthcare · United States · $102M · Avg Vol: $196K/d
6
StockRankGet insider-trade alerts
Q
30
V
22
M
25
P/E (TTM)
—
ROE
-192.2%
D/E
0.0x
Dividend %
—
Loading 1Y...
PRICE (1Y)-17.3%
SMA 50SMA 200
Close
$1.96
RSI (14)
25.2
SCORE BREAKDOWN
Quality
30
ROIC
-103.5%5.9
ROE
-192.2%4.1
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-29.6%11.6
Piotroski
239.0
Int. Cover
—N/A
D/E Ratio
0.00x97.8
Current Ratio
3.45x59.1
Value
22
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
38.7x2.5
P/S
—N/A
Div Yield
—N/A
Momentum
25
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$102M
P/E (Forward)
—
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PLYX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PLYX | Polaryx Therapeutics, Inc.(you) | $102M | 6 | STRONG SELL |
| ONCY | Oncolytics Biotech Inc. | $97M | 5 | STRONG SELL |
| ALDX | Aldeyra Therapeutics, Inc. | $92M | 4 | STRONG SELL |
| SPRB | Spruce Biosciences, Inc. | $119M | 5 | STRONG SELL |
| GUTS | Fractyl Health, Inc. | $123M | 5 | STRONG SELL |
| KLRS | Kalaris Therapeutics, Inc. | $89M | 9 | STRONG SELL |
| CGTX | Cognition Therapeutics, Inc. | $82M | 7 | STRONG SELL |
| HRTX | Heron Therapeutics, Inc. | $86M | 8 | STRONG SELL |
| GNLX | Genelux Corporation | $130M | 7 | STRONG SELL |
| BMEA | Biomea Fusion, Inc. | $90M | 10 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%